Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Agenus (AGEN) Surges 57% on Gilead Deal
December 20, 2018 8:30 AM ESTAgenus (NASDAQ: AGEN) gains 57% in pre-open trade after the company and Gilead Sciences, Inc. (NASDAQ: GILD)... More
